FDA and FTC warn PharmaCanna over CBDefense 2000, a cannabinoid product claimed to prevent or treat COVID-19 without approval.
What happened
FDA reviewed PharmaCanna's website on November 30, 2022, and FTC reviewed it on January 3, 2023; they also reviewed Facebook and YouTube pages that direct consumers to the site. The agencies found CBDefense 2000 offered for sale with claims that it blocks SARS-CoV-2 infection or prevents, treats, diagnoses, or cures COVID-19. FDA says the product is an unapproved new drug and is misbranded.
What FDA found
The company sells CBDefense 2000 as a drug for COVID-19 without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The product is misbranded because its labeling makes misleading drug claims.
section 502 of the FD&C Act, 21 U.S.C. § 352The company introduces or delivers the product into interstate commerce despite these violations.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertises that CBDefense 2000 can prevent or treat COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.The company's COVID-19 claims may trigger civil penalties under the COVID-19 Consumer Protection Act.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA asks PharmaCanna to immediately stop selling unapproved COVID-19 products and, within 48 hours, email FDA with the specific steps taken, an explanation of steps to prevent recurrence, and related documentation. FTC separately asks for certification within 48 hours that the unsubstantiated claims have stopped.
Who should pay attention
- CBD and hemp product sellers making health claims
- online retailers and social media marketers of cannabinoid products
- pharmacies or retailers offered COVID-related supplements
This is a summary. Read the original letter on fda.gov.